Desipramin, Venlafaksin ve Bupropionun Farelerdeki Depresyon ve Anksiyete Üzerine Etkilerinin Zorunlu Yüzme Testi ve Yükseltilmiş Artı Labirent Testi ile Değerlendirilmesi

Yıl 2018, , 820 - 829, 30.12.2018

Mehmet Hanifi Tanyeri Mehmet Emin Büyükokuroğlu , Pelin Tanyeri , Oğuz Mutlu , Füruzan Akar , Güner Ulak , Bekir Faruk Erden

https://doi.org/10.31832/smj.483533

Cited By: 1

Öz

Bu çalışmada, farelerde desipramin, venlafaksin ve bupropiyonun depresyon ve anksiyete üzerine etkilerini araştırmayı amaçladık.
Klasik trisiklik antidepresan, desipramin, serotonin-norepinefrin geri alım inhibitörü venlafaksin ve ikinci jenerasyon antidepresan bir ajan olan noradrenalin ve dopamin gerialım inhibitörü bupropion kullandık. Imipramin (30 mg/kg), desipramin (7,5 mg/kg ve 15 mg/kg), venlafaksin (4 mg/kg ve 8 mg/kg) ve bupropion (20 mg/kg ve 40 mg/kg) FST'de hareketsizlik zamanını önemli ölçüde doza bağlı bir şekilde azalttı. Ayrıca bupropion (40 mg/kg) da imipramine göre anlamlı derecede etkiliydi.

Diazepam (2 mg/kg), desipramin (7.5 mg/kg ve 15 mg/kg), venlafaksin (4 mg/kg ve 8 mg/kg) ve bupropion (20 mg/kg ve 40 mg/kg) EPM'de açık kollarda kalış süresini önemli ölçüde doza bağlı arttırdı.

Diazepam (2 mg / kg), desipramin (7,5 mg/kg ve 15 mg/kg), venlafaksin (8 mg/kg) ve bupropion (20 mg/kg ve 40 mg/kg) açık kola giriş sayısını da artırdı. Ayrıca bupropion (40 mg/kg) diazepamdan anlamlı derecede daha etkiliydi.

Desipramin, venlafaksin ve bupropion (20 mg/kg), imipraminin etkilerinden önemli ölçüde farklı olmayan antidepresan benzeri etkilere neden olmuştur. Bunun yanında bupropion (40 mg/kg) antidepresan benzeri etki göstermiştir ve bu etkiler imipraminden daha güçlüdür. Benzer şekilde, desipramin, venlafaksin ve bupropion (20 mg/kg), diazepamın etkilerinden önemli ölçüde farklı olmayan anlamlı anksiyolitik benzeri etkiler göstermişlerdir. Ayrıca bupropion (40 mg / kg) anlamlı anksiyolitik benzeri etkiler göstermiş ve bu etkiler diazepamdan daha güçlüdür.

Anahtar Kelimeler

desipramin, venlafaksin, bupropion, depresyon, anksiyete

Kaynakça

• 1.Sharp LK, Lipsky MS. Screening for depression across the lifespan: a review of measures for use in primary care settings. Am Fam Physician 2002;66(6):1001-8. 2.Hirschfeld R, Weisssman M (2002). Risk factors for major depression and bipolar disorder. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia pp 1018–1025.3.Merikangas K, Pine D (2002). Genetic and other vulnerability factors for anxiety and stress disorders. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia pp 868–882.4.Thakur P, Rana AC. Effect of cissampelos pareira leaves on anxiety-like behavior in experimental animals. J Tradit Complement Med 2013;3(3):188-93. 5.Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. (1998) The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med60: 458–465.6. Hale VE, Strassberg DS (1990) The role of anxiety on sexual arousal. Arch Sex Behav19: 569–581. 7. Hirschfeld RMA. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(suppl 6):4–6. 8. Brown AS, Gershon S (1993) Dopamine and depression. J Neural Transm Gen Sect 91 (23):75-1099. Paterson NE, Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox Res. 2007 Jan;11(1):1-3210.Wilens TE, Haight BR, Horrigan JP et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005; 57: 793–80111. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph 1993;11(1):2–14.12. Ascher JA, Cole JO, and Colin J-N. et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995 56:395–401. 13. Hull EM, Dominguez JM. Sexual behavior in male rodents. Horm Behav. 2007 Jun;52(1):45-55 14. Segraves RT, Clayton A, Croft H et al. Bupropion sustained release for the treatment of hipoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004;24:339-42
• 15. Tanyeri P, Buyukokuroglu ME, Mutlu O, Ulak G, Yıldız Akar F, Komsuoglu Celikyurt I, Erden BF (imip) Involvement of serotonin receptor subtypes in the antidepressant-like effect of beta receptor agonist Amibegron (SR 58611A): an experimental study.Pharmacol Biochem Behav 2013 Apr;105:12-6.
• 16.Tanyeri P, Buyukokuroglu ME, Mutlu O, Ulak G, Akar FY, Celikyurt IK, Erden BF.Evidence that the anxiolytic-like effects of the beta3 receptor agonist amibegron involve serotoninergic receptor activity. Pharmacol Biochem Behav 2013 Sep;110:27-32.
• 17. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (desip) Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents.J Pharmacol Sci 2004 Jul;95(3):374-80.18. Lu X, Ross B, Sanchez-Alavez M, Zorrilla EP, Bartfai T.Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides 2008 Aug;42(4):387-97.19. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327–336. 20. Porsolt RD, Bertin A, Jalfre M. “Behavioural despair” in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 1978;51:291–294. 21. Maj J, Rogóz Z, Skuza G, Sowińska H. The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist.Neuropharmacology. 1992 Jul;31(7):685-91.22. Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008 Feb;33(3):574-87.
• 23. Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008 Mar;89(1):36-45. 24. Costa AP, Vieira C, Bohner LO, Silva CF, Santos EC, De Lima TC, Lino-de-Oliveira C A proposal for refining the forced swim test in Swiss mice.Prog Neuropsychopharmacol Biol Psychiatry 2013 Aug 1;45:150-5.25. Asakura W1, Matsumoto K, Ohta H, Watanabe HREM sleep deprivation potentiates the effects of imipramine and desipramine but not that of clomipramine in the forced swimming test.Jpn J Pharmacol 1993 Dec;63(4):455-60.26. Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression.Pharmacol Biochem Behav 2008 Jun;89(4):623-627. Overstreet DH, Griebel G. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 2005 Sep;82(1):223-7.
• 28. Overstreet DH, Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 2004 Aug 16;497(1):49-5329. Ide S, Fujiwara S, Fujiwara M, Sora I, Ikeda K, Minami M, Uhl GR, Ishihara K. Antidepressant-like effect of venlafaxine is abolished in μ-opioid receptor-knockout mice.J Pharmacol Sci 2010;114(1):107-10. 30. Kitamura Y, Yagi T, Kitagawa K, Shinomiya K, Kawasaki H, Asanuma M, Gomita Y. Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol 2010 Aug;382(2):151-8.31. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders.Int J Neuropsychopharmacol. 2004 Jun;7(2):193-218. 32. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1) N Engl J Med 1988;319:348–53. 33. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000;405:365–373. 34. Dziedzicka-Wasylewska M, Kolasiewicz W, Rogoz Z, Margas W, Maj J. The role of dopamine D2 receptor in the behavioral effects of imipramine - study with the use of antisense oligonucleotides. J Physiol Pharmacol 2000;51:401–409. 35. D'Aquila PS, Canu S, Sardella M, Spanu C, Serra G, Franconi F.Dopamine is involved in the antidepressant-like effect of allopregnanolone in the forcedswimmingtest in female rats.Behav Pharmacol 2010 Feb;21(1):21-836. Yamada J, Sugimoto Y, Yamada S.Involvement of dopaminereceptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test.Eur J Pharmacol 2004 Nov 19;504(3):207-1137. Leggio GM, Torrisi SA, Castorina A, Platania CB, Impellizzeri AA, Fidilio A, Caraci F, Bucolo C, Drago F, Salomone S.Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. Eur Neuropsychopharmacol 2014 Nov 15. pii: S0924-977X(14)00301-0. 38. Bitran D, Hull EM. Pharmacological analysis of male rat sexual behavior. Neurosci Biobehav Rev 1987; 11: 365 – 389.39. Shindel AW, Eisenberg ML, Breyer BN, Sharlip ID, Smith JF. Sexual function and depressive symptoms among female North American medical students. J Sex Med. 2011;15:391–399. 40. Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: Conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev. 2009;29:573–85. 41. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166.42. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor–induced sexual dysfunction. J Clin Psychiatry. 1998;59:112–115.43. Gitlin MJ, Suri R, and Alshuler L. et al. Bupropion sustained release as a treatment of SSRI-induced sexual side effects. J Sex Marital Ther 2002 28:131–138. 44. Kennedy SH, McCann SM, and Masellis M. et al. Combining bupropion SR with venlafaxine, paroxetine, and fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002 63:181–186. 45. Labatte LA, Grimes JB, and Hines A. et al. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry 1997 9:241–245. 46. Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla.